作为糖尿病病治疗的β-上腺素受体激活剂
Ehtesham Arif1, Danira Medunjanin2,3, Ashish Solanki1
1Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, United States.
American journal of physiology. Renal physiology
|November 2, 2023
概括
甲醇是一种β-2上腺素受体激动剂,在小鼠模型中逆转了糖尿病病. 在患有慢性脏疾病的人类退伍军人中,β-2上腺素受体激动剂与减少进展到末期脏疾病有关.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 药理学 药理学是指药理学的学科.
- 肺部病理学 肺部病理学
背景情况:
- 糖尿病病是末期病 (ESKD) 的主要原因之一.
- 长效β2上腺素受体 (β2-AR) 激动剂,如formoterol,已经显示出治疗损伤的潜力.
- 了解β2-AR激动剂在糖尿病病和慢性病 (CKD) 进展中的作用至关重要.
研究的目的:
- 在小鼠模型中研究甲醇对糖尿病病的保护作用.
- 在人类队列中检查β2-AR激动剂使用与CKD向ESKD进展之间的关联.
主要方法:
- 用1型和2型糖尿病的小鼠模型 (链毒素和高脂肪饮食) 来评估formoterol在糖尿病病中的疗效.
- 在全国一群患有第四阶段CKD的退伍军人身上进行了竞争性风险回归分析,以评估COPD,β2-AR激动剂使用和ESKD进展之间的关联.
主要成果:
- 在1型和2型糖尿病小鼠模型中,formoterol治疗导致了糖尿病脏病的显著恢复和逆转.
- 在患有第四期CKD的人类退伍军人中,COPD的存在 (与β2-AR激动剂使用相关) 与25.6%的ESKD进展率降低有关.
- 敏感性分析显示,那些使用长期起作用的形式醇的人的ESKD减少了33.2%,而其他β2-AR激动剂的ESKD减少了20.8%.
结论:
- 贝塔2上腺素受体激动剂,特别是形式醇,显示出作为糖尿病病治疗策略的潜力.
- 在患有慢性病和COPD的患者中,服用β2-AR激动剂与进展到末期病的风险降低有关.
- 这些发现表明,治疗糖尿病病和其他形式的慢性病的新途径.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
438
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
438
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
750
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
750
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
493
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
493
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
212
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
212
01:22Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
869
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
869
01:17Antihypertensive Drugs: Action of β1 Blockers
455
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
455